Veraxa Biotech Holding AG (VRXA)
Veraxa Biotech Holding AG operates in the Biotechnology industry of the Healthcare sector, headquartered in Heidelberg, ZH, DE. The stock last traded at $1.04, up 0.97% on the session, giving a market capitalisation of $147.1M. Its beta of 0.26 implies it has historically moved less than the broad market.
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation. The company was founded in 2021 and is based in Heidelberg, Germany.